Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ozuriftamab vedotin by BioAtla for Soft Tissue Sarcoma: Likelihood of Approval
Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...
Ozuriftamab vedotin by BioAtla for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Ozuriftamab vedotin is under clinical development by BioAtla and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Risk adjusted net present value: What is the current valuation of BioAtla's Ozuriftamab vedotin?
Ozuriftamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Soft Tissue Sarcoma....
Risk adjusted net present value: What is the current valuation of BioAtla's Ozuriftamab vedotin?
Ozuriftamab vedotin is a monoclonal antibody conjugated commercialized by BioAtla, with a leading Phase II program in Oropharyngeal Cancer. According...